Literature DB >> 7867683

Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects.

J X Sun1, A Cipriano, K Chan, V A John.   

Abstract

Pharmacokinetic interaction between benazepril (ACE inhibitor) and amlodipine (calcium channel blocker) was studied in 12 healthy subjects. Single doses of benazepril hydrochloride (10-mg tablet) and amlodipine besylate (tablet equivalent to 5 mg amlodipine) were administered alone or in combination according to a three-way, Latin-Square, randomized cross-over design. Serial blood samples were collected following each administration for the determination of benazepril and its active metabolite benazeprilat and amlodipine. The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.ml-1, and 0.5 vs 0.6 h. The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.ml-1, and 1.7 vs 1.5 h. The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.ml-1, and 8.3 vs 9.0 h. The differences in these pharmacokinetic parameters between the combination and monotherapy treatments were not statistically significant based on ANOVA. The results of this study indicate that no pharmacokinetic interaction existed between the two drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7867683     DOI: 10.1007/bf02570510

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

Review 1.  Dose-response studies with benazepril in mild to moderate hypertension.

Authors:  H J Gomez
Journal:  Clin Cardiol       Date:  1991-08       Impact factor: 2.882

Review 2.  Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide.

Authors:  V DeQuattro
Journal:  Clin Cardiol       Date:  1991-08       Impact factor: 2.882

3.  Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study.

Authors:  A Salvetti; P F Innocenti; M Iardella; F Pambianco; G C Saba; M Rossetti; G F Botta
Journal:  J Hypertens Suppl       Date:  1987-12

4.  Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers.

Authors:  M D Schaller; J Nussberger; B Waeber; J P Bussien; G A Turini; H Brunner; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  D Murdoch; R C Heel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

6.  Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.

Authors:  D R Abernethy; J Gutkowska; L M Winterbottom
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

Review 7.  Clinical pharmacokinetics of amlodipine.

Authors:  P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 8.  The use of benazepril in hypertensive patients age 55 and over.

Authors:  W M Smith; H J Gomez
Journal:  Clin Cardiol       Date:  1991-08       Impact factor: 2.882

9.  Captopril and nifedipine in combination for moderate to severe essential hypertension.

Authors:  D R Singer; N D Markandu; A C Shore; G A MacGregor
Journal:  Hypertension       Date:  1987-06       Impact factor: 10.190

10.  An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1987-12       Impact factor: 3.105

View more
  4 in total

1.  Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension.

Authors:  M U Naidu; P R Usha; T R Rao; J C Shobha
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

Review 2.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

3.  Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers.

Authors:  Kuo-Liong Chien; Chia-Lun Chao; Ta-Cheng Su
Journal:  Curr Ther Res Clin Exp       Date:  2005-03

Review 4.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.